Tolganay Kulatay

Tolganay Kulatay

Auto-generated profile, based on publicly available information

Tolganay Kulatay

National Center for Biotechnology, Korgalzhin hwy 13/5, Astana 010000, Kazakhstan

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2024 in Biotechnology and Bioengineering
Verified
Journal Article
Closed access
VKViktoriya Keyer
Viktoriya Keyer
LSLaura Syzdykova
Laura Syzdykova
BIBakytkali Ingirbay
Bakytkali Ingirbay
ESElena Sedova
Elena Sedova
GZGulzat Zauatbayeva
Gulzat Zauatbayeva
ASAlexandr V. Shustov
Alexandr V. Shustov

14 August 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
VKViktoriya Keyer
Viktoriya Keyer
AKAitolkyn Kydyrbayeva
Aitolkyn Kydyrbayeva
TKTolganay Kulatay
Tolganay Kulatay
GZGulzat Zauatbayeva
Gulzat Zauatbayeva
DBDmitrii Bazhenov
Dmitrii Bazhenov
ASAlexandr V. Shustov
Alexandr V. Shustov
CAR-T cell therapy represents a breakthrough in cancer treatment, yet its implementation in developing countries remains challenging due to technical and infrastructural barriers. This study aimed to establish clinical-scale CAR-T production in Kazakhstan, a country with no prior experience in advanced cell and gene therapies. We implemented a complete CAR-T manufacturing pipeline, including in-house lentiviral vector (LV) production and automated CAR-T cell processing using the CliniMACS Prodigy system. Two anti-CD19 CAR LVs were used, one modeled after FDA-approved Kymriah (4-1BB costimulation) and another replicating Yescarta (CD28 costimulation). The vector produced locally achieved functional titers of 1.5 × 1010 TU/mL after concentration. Twelve clinical-scale CAR-T products were manufactured, exhibiting a memory-skewed T-cell phenotype. Functional assessments revealed that CD28-based CAR-T cells produced significantly higher Th1 cytokines (IFN-γ, TNF-α, IL-2; p < 0.05) than 4-1BB-based cells, though both demonstrated comparable cytotoxicity against CD19+ targets. These findings demonstrate the feasibility of establishing CAR-T production in resource-limited settings using a decentralized manufacturing framework. This work provides a scalable model of CAR-T therapy production in developing regions, suitable for clinical implementation using the hospital exemption framework. Critical gaps in access to advanced immunotherapies, including CAR-T, in the Central Eurasia region are addressed.

13 February 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
GZGulzat Zauatbayeva
Gulzat Zauatbayeva
TKTolganay Kulatay
Tolganay Kulatay
BIBakytkali Ingirbay
Bakytkali Ingirbay
ZSZhanar Shakhmanova
Zhanar Shakhmanova
VKViktoriya Keyer
Viktoriya Keyer
ASAlexandr V. Shustov
Alexandr V. Shustov
Transient gene expression (TGE) is commonly employed for protein production, but its reliance on plasmid transfection makes it challenging to scale up. In this paper, an alternative TGE method is presented, utilizing pseudoinfectious alphavirus as an expression vector. Pseudoinfectious viruses (PIV) and a replicable helper construct were derived from the genome of the Venezuelan equine encephalitis virus. The PIV carries a mutant capsid protein that prevents packaging into infectious particles, while the replicable helper encodes a wild-type capsid protein but lacks other viral structural proteins. Although PIV and the helper cannot independently spread infection, their combination results in increased titers in cell cultures, enabling easier scale-up of producing cultures. The PIV-driven production of a model protein outperforms that of alphavirus replicon vectors or simple plasmid vectors. Another described feature of the expression system is the modification to immobilized metal affinity chromatography (IMAC), allowing purification of His-tagged recombinant proteins from a conditioned medium in the presence of substances that can strip metal from the IMAC columns. The PIV-based expression system allows for the production of milligram quantities of recombinant proteins in static cultures, without the need for complex equipment such as bioreactors, and complies with regulatory requirements due to its distinction from common recombinant viruses.

30 September 2025 in Eurasian Journal of Applied Biotechnology
Verified
Journal Article
Open access
PDF file
TKT. Kulatay
T. Kulatay
ESE. Sedova
E. Sedova
ASA. Shevtsov
A. Shevtsov
GZG. Zauatbayeva
G. Zauatbayeva
BIB. Ingirbay
B. Ingirbay
ASA. Shustov
A. Shustov
Tick-borne encephalitis virus (TBEV) is a reemerging pathogen in Kazakhstan. Despite the availability of inactivated TBEV vaccines produced abroad, their reliance on complex multi-dose regimens and frequent boosters limits their implementation for routine use in Kazakhstan. New technologies, including chimerization of different Flavivirus species, enable the development of vaccine candidates which require only a single dose to achieve long-lasting immunity. The ChimeriVax platform leverages the efficient replication machinery of the yellow fever virus (YFV) 17D vaccine strain engineered to express the structural proteins of a different flavivirus. In this work, the ChimeriVax YFV/TBEV virus was created by replacing the prM-E genes in the YFV genome with the prM-E genes of TBEV. Preclinical evaluation demonstrated robust replication (~10^8 focus-forming units, FFU/mL) in cell cultures and genetic stability over multiple passages. In murine models, the chimeric virus elicited transient viremia (peaking at 10^4 FFU/mL) without mortality even at high doses (10^5 FFU). Immunization induced potent neutralizing antibodies (geometric mean titer: 4,076) and robust cellular immunity, marked by production of the cytokines IFN-γ, TNF-α, and IL-2 upon antigen stimulation. These results position the ChimeriVax YFV/TBEV virus as a promising vaccine candidate.

20 August 2026 in Bioengineering
Verified
Journal Article
Open access
PDF file
GNGaziza Nigmatulla
Gaziza Nigmatulla
AKAitolkyn Kydyrbayeva
Aitolkyn Kydyrbayeva
TKTolganay Kulatay
Tolganay Kulatay
GZGulzat Zauatbayeva
Gulzat Zauatbayeva
BIBakytkali Ingirbay
Bakytkali Ingirbay
ASAlexandr V. Shustov
Alexandr V. Shustov
The growing demand for high-quality plasmid DNA (pDNA) in cell and gene therapy, including chimeric antigen receptor T-cell therapy (CAR-T) manufacturing, is constrained by the limited availability of transfection-grade plasmids. This study describes a practical, scalable, and cost-effective acidic phenol extraction method based on a modified alkaline lysis protocol. This approach efficiently removes endotoxins and residual genomic DNA without requiring chromatography or ultracentrifugation. When benchmarked against CsCl density gradient ultracentrifugation and a commercial midiprep kit, the acidic phenol method delivered comparable plasmid purity and functional performance while providing superior scalability, yielding 5–10 mg of pDNA per 500 mL culture. Notably, residual endotoxin levels were negligible for downstream applications such as transfection and lentiviral vector packaging. Lentiviral vectors produced with these plasmids reached titers exceeding 5 × 106 TU/mL, with transduction efficiencies statistically indistinguishable from those obtained with CsCl-purified DNA. The acidic phenol extraction method is a robust, scalable, and cost-effective alternative to industry-standard methods, matching them in yield and purity while being readily scalable, making it a practical tool for both academic research and preparative laboratory production.

24 January 2026 in Biology
Verified
Journal Article
Open access
PDF file
PTPavel Tarlykov
Pavel Tarlykov
BIBakytkali Ingirbay
Bakytkali Ingirbay
DADana Auganova
Dana Auganova
TKTolganay Kulatay
Tolganay Kulatay
VKViktoriya Keyer
Viktoriya Keyer
ASAlexandr V. Shustov
Alexandr V. Shustov
The flavivirus NS1 protein is a component of the viral replication complex and plays diverse, yet poorly understood, roles in the viral life cycle. To enable real-time visualization of the developing replication organelle and biochemical analysis of tagged NS1 and its interacting partners, we engineered a replication-competent yellow fever virus (YFV) replicon encoding a C-terminal fusion of NS1 with green fluorescent protein (NS1-GFP). The initial variant was non-viable in the absence of trans-complementation with wild-type NS1; however, viability was partially restored through the introduction of co-adaptive mutations in GFP (Q204R/A206V) and NS4A (M108L). Subsequent cell culture adaptation generated a 17-nucleotide frameshift within the NS1-GFP linker, resulting in a more flexible and less hydrophobic linker sequence. The optimized genome, in the form of a replicon, replicates in packaging cells that produce YFV structural proteins, as well as in naive BHK-21 cells. In the packaging cells, the adapted NS1-GFP replicon produces titers of infectious particles of approximately 106 FFU/mL and is genetically stable over five passages. The expressed NS1-GFP fusion protein localizes to the endoplasmic reticulum and co-fractionates with detergent-resistant heavy membranes, a hallmark of flavivirus replication organelles. This NS1-GFP replicon provides a novel platform for studying NS1 functions and can be further adapted for proximity-labeling strategies aimed at identifying the still-unknown protease responsible for NS1-NS2A cleavage.